Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons

Raehannah J. Jamshidi, Laura C. Sullivan, Blaine A. Jacobs, Teresa A. Chavera, Kelly A. Berg, and William P. Clarke

ABSTRACT

A single administration of the kappa opioid receptor (KOR) antagonist, norbinaltorphimine (norBNI), produces long-term reduction in KOR function in heterologous expression systems and brain that is mediated by activation of c-Jun N-terminal kinase (JNK). In this study, we examined the long-term effects of norBNI on adult rat peripheral sensory neurons in vivo and ex vivo. Following a single intraplantar (i.pl.) injection of norBNI into the hind paw, peripheral KOR-mediated antinociception in the ipsilateral, but not the contralateral, hindpaw was abolished for at least 9 days. By contrast, the antinociceptive response to mu and delta opioid receptor agonists was unaltered. The long-term inhibitory effect on antinociception produced by pretreatment with norBNI required occupancy of peripheral KOR and was completely blocked by i.pl. injection of the JNK inhibitor, SP600125. In cultures of peripheral sensory neurons, norBNI activated JNK for at least 30 minutes. Furthermore, norBNI blocked KOR-mediated inhibition of adenylyl cyclase activity measured 24 hours later in a JNK-dependent manner, but did not block activation of extracellular signal-regulated kinase (ERK). The long-term inhibitory effect of norBNI on KOR function in vivo and ex vivo was blocked by inhibitors of mRNA translation, cycloheximide and rapamycin. These data suggest that in peripheral sensory neurons norBNI is a KOR-biased ligand for activation of JNK signaling, resulting in long-term blockade of some (antinociception, inhibition of adenylyl cyclase activity), but not all (ERK), KOR signaling. Importantly, norBNI elicits de novo protein synthesis in sensory neuron terminals that produces selective long-term regulation of KOR.

Introduction

Kappa opioid receptors (KORs) are expressed widely throughout the central nervous system (CNS) and regulate several physiologic functions and behaviors, including pain, depression, anxiety, and drug-seeking (Pfeiffer et al., 1986; Shippenberg and Herz, 1986; Todtenkopf et al., 2004; Bruchas et al., 2007a; Redila and Chavkin, 2008; Butelman et al., 2012; Zhou et al., 2013). KORs are also expressed by pain-sensing neurons (nociceptors) of the peripheral nervous system, where they function to inhibit transmission of pain stimuli to the CNS (Fields et al., 1980; Chen et al., 1997; Stein and Lang, 2009; Stein and Zollner, 2009; Berg et al., 2011; Jamshidi et al., 2015). It has been suggested that peripherally-restricted KOR agonists may provide for improved treatment of some forms of pain that would be devoid of CNS-mediated adverse effects (Kivell and Priszinzano, 2010; Vanderah, 2010; Berg et al., 2011; Vadivelu et al., 2011; Jamshidi et al., 2015), and some clinical studies have demonstrated efficacy of peripherally-restricted KOR agonists in a variety of pain conditions (Riviere, 2004; Arendt-Nielsen et al., 2009). Opioid receptor systems expressed in nociceptors are regulated differently from their CNS counterparts. Although activation of opioid receptors by the CNS readily elicits antinociception (see Pasternak and Pan, 2013), local administration of opioids to nociceptors at peripheral-restricted doses does not produce antinociception in normal tissue (Joris et al., 1987; Przewlocki and Przewlocka, 2001; Obara et al., 2009; Rowan et al., 2009; Stein and Zollner, 2009; Berg et al., 2011, 2012). However, following inflammation or tissue injury, robust antinociceptive responses to peripheral administration of opioids occur (Fields et al., 1980; Chen et al., 1997; Obara et al., 2009; Rowan et al., 2009; Aarens et al., 2009; Pasternak and Pan, 2013).

ABBREVIATIONS: ANOVA, analysis of variance; AUC, area under the curve; BK, bradykinin; CHX, cycloheximide; CNS, central nervous system; DAMGO, [D-Ala²,N-MePhe⁴,Gly-ol⁵]-enkephalin; DOR, μ opioid receptor; DPDPE, [D-Pen²,⁵]-enkephalin; ERK, extracellular signal-regulated kinase; GPCR, G protein-coupled receptor; i.pl., intraplantar; JNK, c-Jun N-terminal kinase; KOR, κ opioid receptor; MOR, μ opioid receptor; norBNI, norbinaltorphimine; pERK, phosphorylated ERK; PGE₂, prostaglandin E₂; pJNK, phosphorylated JNK; PWL, paw withdrawal latency; RAPA, rapamycin.
2009; Stein and Lang, 2009; Stein and Zollner, 2009; Berg et al., 2011; Sullivan et al., 2015). Similarly, opioid agonists do not produce inhibitory signaling in cultures of nociceptors unless the cells are first pretreated with an inflammatory mediator, such as bradykinin or arachidonic acid (Patwardhan et al., 2005; Berg et al., 2007, 2011; Sullivan et al., 2015).

Because KOR may be a viable peripheral target for pain pharmacotherapy, it is important to understand the regulation of KOR function in peripheral nociceptors. Several studies have shown that a single systemic injection of the prototypical KOR antagonist, norbinaltorphimine (norBNI), inhibits KOR-mediated antinociception for up to 3 weeks (Endoh et al., 1992; Horan et al., 1992; Jones and Holtzman, 1992; Butelman et al., 1993; Broadbear et al., 1994; Bruchas et al., 2007b; Melief et al., 2010, 2011). Similar long-term inhibition of KOR function occurs in pigeons (Jewett, 1995), heterologous expression systems (Bruchas et al., 2007b; Melief et al., 2010, 2011), and with other, but not all, KOR antagonists (Melief et al., 2011). Such long-term drug effects are often attributed to irreversible occupancy of a receptor. However, norBNI has been shown to be a selective, competitive KOR antagonist (Portoghese et al., 1987a,b), and the long-term effect of norBNI can be blocked by competitive antagonists (Bruchas et al., 2007b), suggesting that the long-term action of norBNI is not due to irreversible receptor occupancy. In an elegant series of experiments, Chavkin and colleagues (Bruchas et al., 2007b; Melief et al., 2010, 2011) demonstrated that norBNI acts as a KOR agonist to activate c-Jun N-terminal kinase (JNK) in a pertussis toxin-insensitive manner and that pharmacological inhibition of JNK, or JNK 1 knockout, prevents the long-term effects of norBNI in HEK cells and in mice. On the basis of this work, they proposed that a hypothetical JNK-sensitive substrate associates with KOR to block KOR signaling (Bruchas et al., 2007b; Bruchas and Chavkin, 2010; Melief et al., 2010, 2011).

Given that regulation of KOR function in nociceptors often differs from that in other tissues/cells, in this study we sought to determine whether long-term inhibitory control of KOR also occurred in nociceptors ex vivo and in vivo. We found that stimulation of KOR with norBNI produced a long-lasting reduction in some, but not all, KOR functional responses in nociceptors. Moreover, the long-term effects of norBNI were mediated by JNK-sensitive activation of protein translation in peripheral sensory neuron terminals. These results support the conclusion that norBNI is a biased KOR ligand, leading to activation of JNK (but not Gori-mediated signaling), which initiates local, de novo protein synthesis in sensory neuron terminals and long-term inhibition of some aspects of KOR signaling.

Materials and Methods

Drugs and Chemicals. The following compounds were purchased from Sigma-Aldrich (St. Louis, MO): bradykinin (BK) acetate salt, rolipram, norBNI dihydrochloride, (-)-trans-(1S, 2S)-U50488 hydrochloride hydrate (US0488), JNK inhibitor (SP600125), and cycloheximide solution (CHX). Rapaycin (RPA) was purchased from LC Laboratories (Woburn, MA). Prostaglandin E2 (PGE2) was purchased from Cayman Chemical (Ann Arbor, MI). D-Pen2,5-Enkephalin (DPEP) was purchased from Bachem (Torrance, CA). Salvinorin-A was a gift of T. Prisinzano (Kansas City, MO). 125I-CAMP was purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). Nerve growth factor was purchased from Harlan Laboratories (Indianapolis, IN), collagenase from Worthington Biochemicales (Freehold, NJ), and all other tissue culture reagents were purchased from Life Technologies (Grand Island, NY).

Animals. Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA), weighing 250–300 g, were used in this study. The animal study protocol was approved by the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio and conformed to the International Association for the Study of Pain and federal guidelines. Animals were housed for 1 week, with food and water available ad libitum, before experimentation.

Behavioral Assay. Opioid agonist-mediated changes in paw withdrawal latency (PWL) to a radiant heat stimulus were measured with a plantar test apparatus (Hargreaves et al., 1988), as described previously (Berg et al., 2011; Jamshidi et al., 2015). The radiant heat stimulus was set to produce baseline PWL of 10 ± 2 seconds with a cutoff time of 25 seconds to prevent tissue damage. After baseline PWL was determined, animals were pretreated with BK (25 μg) via intraplantar (i.pl.) injection to induce KOR functional competence (Rowan et al., 2009; Berg et al., 2011, 2012; Jamshidi et al., 2015; Sullivan et al., 2015). To assess KOR-mediated antinociception, rats received coinjections (i.p.l.) of PGE2 (0.3 μg) with vehicle or U50488 (0.1 μg) 15 minutes after the BK injection. PWL measurements were obtained in duplicate (at least 30 seconds apart) before and at 5-minute intervals following opioid/vehicle injection for 20 minutes. To assess long-term effects, norBNI (0.3–30 ng) or vehicle was injected (i.pl.)/2, 7, or 9 days before testing KOR function. In some experiments, SP600125 (1 μg) or vehicle was administered (i.pl.) 24 hours and 30 minutes prior to injection (i.pl.) of norBNI. Where indicated, CHX (25 μg) or RAPA (12 μg) was administered (i.pl.) 30 minutes prior to and 24 hours following injection (i.pl.) of norBNI. Time course data are expressed as the change (seconds) from individual PWL baseline values and represent mean ± S.E.M. of six rats per group. Area under the curve (AUC) data were quantified from each individual time course curve. All drugs were administered (i.pl.) at a volume of 50 μl. Investigators were blind to the treatment allocation.

Primary Sensory Neuronal Cultures. Primary cultures derived from rat trigeminal ganglion were prepared, as described previously (Patwardhan et al., 2005, 2006; Berg et al., 2007, 2011; Jamshidi et al., 2015; Sullivan et al., 2015), and maintained in culture for 5 days. For all experiments, cells were fed with serum-free Dulbecco’s modified Eagle’s medium without nerve growth factor on day 5 and used for experiments on the sixth day of culture (i.e., after a 24-hour serum- and nerve growth factor-free period). Opioid receptors colocalize with bradykinin B2 receptors that are expressed on TRPV1-expressing peripheral sensory neurons (Patwardhan et al., 2005; Jeske et al., 2006; Patwardhan et al., 2006; Berg et al., 2007, 2011; Rowan et al., 2009; Gomez et al., 2011) along with receptors for prostaglandin E2 (Patwardhan et al., 2008). In addition, activation of bradykinin B2 receptors induces functional competence of opioid receptors expressed on peripheral pain-sensing neurons for reduction of PGE2-stimulated cAMP accumulation ex vivo and for reduction of PGE2-evoked thermal allodynia in vivo (Patwardhan et al., 2005; Berg et al., 2007, 2011; Rowan et al., 2009). In these experiments, we measured KOR-mediated inhibition of PGE2-mediated responses in vivo and ex vivo following induction of functional competence with bradykinin. Thus, we interpret the long-term effects of norBNI, both ex vivo (e.g., Fig. 5) and in vivo (e.g., Fig. 1), as due to the interaction of norBNI with KOR coexpressed with bradykinin B2 and PGE2 receptors on peripheral sensory neurons.

Measurement of Cellular cAMP Accumulation. Opioid receptor-mediated inhibition of adenyl cyclase activity was determined by measuring the amount of cAMP accumulated (15 minutes) in the presence of the phosphodiesterase inhibitor, rolipram, and PGE2 (1 μM) with or without the indicated opioid receptor ligands, as described previously (Patwardhan et al., 2005, 2006; Berg et al., 2007, 2011; Jamshidi et al., 2015; Sullivan et al., 2015). For all experiments, cells were pretreated with BK (10 μM, 15 minutes, 37°C) to induce KOR functional competence (Berg et al., 2007, 2011, 2012; Jamshidi et al., 2015; Sullivan et al., 2015). To assess KOR-mediated antinociception, rats received coinjections (i.p.l.) of PGE2 (0.3 μg) with vehicle or U50488 (0.1 μg) 15 minutes after the BK injection. PWL measurements were obtained in duplicate (at least 30 seconds apart) before and at 5-minute intervals following opioid/vehicle injection for 20 minutes. To assess long-term effects, norBNI (0.3–30 ng) or vehicle was injected (i.pl.)/2, 7, or 9 days before testing KOR function. In some experiments, SP600125 (1 μg) or vehicle was administered (i.pl.) 24 hours and 30 minutes prior to injection (i.pl.) of norBNI. Where indicated, CHX (25 μg) or RAPA (12 μg) was administered (i.pl.) 30 minutes prior to and 24 hours following injection (i.pl.) of norBNI. Time course data are expressed as the change (seconds) from individual PWL baseline values and represent mean ± S.E.M. of six rats per group. Area under the curve (AUC) data were quantified from each individual time course curve. All drugs were administered (i.pl.) at a volume of 50 μl. Investigators were blind to the treatment allocation.
et al., 2015; Sullivan et al., 2015). To assess long-term effects of norBNI on KOR agonist-mediated inhibition of PGE2-stimulated cAMP accumulation, cells were treated with norBNI (3 nM) for 1 hour, washed three times with 500 μl/well serum-free media (a total wash period of 30 minutes), and then incubated further for 24 hours (37°C, 5% CO2) before testing KOR agonist efficacy. In some experiments, cells were pretreated with CHX (1 μM), RAPA (1 μM), or SP600125 (1 μM) 30 minutes prior to norBNI. Incubations were terminated by aspiration of the buffer and addition of 500 μl ice-cold absolute ethanol. The ethanol extracts from individual wells were dried under a gentle air stream and reconstituted in 100 μl 50 mM sodium acetate, pH 6.2. The cAMP content of each well was determined by radioimmunoassay.

Measurement of Extracellular Signal-Regulated Kinase 1/2 Activation. The κ agonist-mediated activation of extracellular signal-regulated kinase (ERK) was determined as described previously (Berg et al., 2011; Jamshidi et al., 2015). ERK activation was assessed by measuring the levels of phosphorylated ERK (pERK) produced in response to treatment of cells with U50488 (100 nM) for 0–15 minutes. pERK was measured with the AlphaScreen SureFire Phospho-ERK 1/2 Kit (PerkinElmer Life and Analytical Sciences), according to manufacturers' instructions, and a Fluostar microplate reader equipped with AlphaScreen technology (BMG Labtech, Ortenberg, Germany). To assess the long-term effect of norBNI on KOR-mediated ERK activation, cells were pretreated with norBNI (3 nM) for 1 hour and then washed three times with 500 μl (per well) serum-free media (for a total of 30-minute wash period) and incubated for 24 hours (37°C, 5% CO2) before measurement of U50488 stimulation of ERK. To assess the effect of acute norBNI treatment, cells were pretreated with norBNI (3 nM) for 15 minutes before incubation with U50488 (100 nM).

Measurement of JNK Activation. The levels of phosphorylated JNK (pJNK), as an index of JNK activity, in response to norBNI treatment were determined by Western analysis, as we have described previously (Jamshidi et al., 2015). Briefly, peripheral sensory neurons were plated in six-well plates and maintained in culture, as described above. Cells were washed with 4 ml/well Hanks' balanced salt solution containing 20 mM HEPES (pH 7.4) and incubated for 15 minutes at 37°C before addition of ligands. Cells were then treated with vehicle or norBNI (3 nM) for 5–60 minutes at 37°C in the presence of phosphatase inhibitor cocktail 3 (0.1%; Sigma-Aldrich) and okadaic acid (10 nM; Sigma-Aldrich). Incubation was terminated by aspiration...
Thermal Allodynia by Activation of JNK.

PGE2-induced thermal allodynia (mediated antinociception by norBNI without affecting either (i.pl.), completely blocked the long-term reduction in U50488-mediated antinociception (Bruchas et al., 2007b; Melief et al., 2010, 2011), so we tested whether long-term effects of norBNI on U50488-JNK (Bruchas et al., 2007b; Melief et al., 2010, 2011), so we imaged using a Li-Cor infrared Odyssey Imager (Li-Cor Biosciences), used to detect pJNK and actin, respectively. Immunoblots were collected and prepared for SDS-PAGE following the NuPAGE protocol (Pierce, Thermo Scientific) per well. Cells were scraped and centrifuged 2000 rpm at 4°C for 3 minutes, and the supernatant was collected and prepared for SDS-PAGE following the NuPAGE protocol (Novex, Life Technologies, Grand Island, NY). Blots were probed with anti-rat phospho–stress-activated protein kinase/JNK (81E11) rabbit monoclonal antibody (catalog 4688; Cell Signaling, Danvers, MA), which is the same antibody that we have used to measure pJNK levels previously (Jamshidi et al., 2015) and has been used by the Chavkin group in their studies of KOR regulation of JNK (e.g., Melief et al., 2011). This antibody has been validated by the company for Western analysis using cell lysates of native HEK293, NIH3T3, and C6 cells, and results have been validated using JNK knockout mice (Melief et al., 2011). In all samples, actin was probed with an anti-rat actin goat polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) as a loading control. Goat anti-rabbit IR800 and donkey anti-goat IR680 secondary antibodies (Li-Cor Biosciences, Lincoln, NE) were used to detect pJNK and actin, respectively. Immunoblots were imaged using a Li-Cor infrared Odyssey Imager (Li-Cor Biosciences), and relative band intensities were quantified using Odyssey software (Li-Cor Biosciences).

Data Analysis. For cell culture experiments, statistical significance was assessed using one-way analysis of variance (ANOVA), followed by Dunnett’s post hoc or Student’s t-test (paired) using Prism software (GraphPad Software, San Diego, CA). P < 0.05 was considered statistically significant.

For behavioral experiments, time course data were analyzed with two-way ANOVA, followed by Bonferroni’s post hoc test to compare treatment effects over time using Prism software. Area under the time-response curves for individual rats was calculated, and mean values were analyzed with one-way ANOVA, followed by Dunnett’s post hoc test using Prism software. P < 0.05 was considered as statistically significant. Data are presented as mean ± S.E.M.

Results

Treatment with norBNI Produces Long-Term Reduction of KOR-Mediated Inhibition of PGE2-Evoked Thermal Allodynia by Activation of JNK. Intraplantar injection of PGE2 produced a prolonged (>20 minutes) allodynia, as shown by a reduction in PWL (4–5 seconds) (Supplemental Fig. 1). Coinjection of U50488 completely inhibited PGE2-stimulated thermal allodynia and produced robust antinociception (PWL was above preinjection baseline values) (Fig. 1, A and B; Supplemental Fig. 1). A single injection (i.pl.) of norBNI administered 2 or 7 days earlier abolished the U50488-mediated inhibition of PGE2-stimulated thermal alldynia. norBNI did not alter the alldynia produced by PGE2.

Studies done in CNS neurons have shown that long-term reduction of KOR function by norBNI is due to activation of JNK (Jamshidi et al., 2015; Bruchas et al., 2007b; Melief et al., 2010, 2011), so we next tested whether long-term effects of norBNI on U50488-mediated antithermal alldynia in the rat hind paw were JNK mediated. Pretreatment with the JNK inhibitor, SP600125 (i.pl.), completely blocked the long-term reduction in U50488-mediated antinociception by norBNI without affecting either PGE2-induced thermal alldynia (∼63.6 ± 15.6 versus −46.51 ± 12.5; AUC values for vehicle versus SP600125 treatment, respectively) or U50488-mediated antinociception (38.2 ± 12.7 versus 15.0 ± 11.8 AUC values for vehicle versus SP600125, respectively). Consistent with blockade of the long-term effect of norBNI by pharmacological inhibition of JNK, treatment of primary sensory neuron cultures with norBNI increased pJNK levels (i.e., JNK activity) for about 30 minutes (Fig. 1C).

Figure 2 (and Supplemental Fig. 2) shows that injection of norBNI (i.pl.) also blocked the antinociceptive effect of the highly selective KOR agonist, Salvinorin-A, when tested 9 days after norBNI injection. By contrast, neither the antinociceptive response to the δ opioid receptor (DOR) agonist, DPDPDE, nor to the μ opioid receptor (MOR) agonist, [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin (DAMGO), was altered by norBNI.

Long-Term Effects of norBNI Are Mediated by KOR. To determine whether the long-term effects of norBNI were due to interaction with KOR, we attempted to reduce occupancy of KOR by norBNI with a relatively higher dose of U50488. We first conducted a dose response for norBNI to produce long-term inhibition of KOR-mediated antinociception (Supplemental Fig. 3) and determined that a dose of 3 ng norBNI (i.pl.) was effective at blocking U50488-mediated antinociception 2 days after the norBNI injection. Based upon an assumption that the volume of distribution in the hind paw following injection (i.pl.) was 1 ml, the concentration of norBNI, injected at a dose of 3 ng, would be 3 nM, which is 100 × Ki of norBNI for KOR. To reduce occupancy of KOR produced by this concentration of norBNI with U50488 (assuming the same volume of distribution and a Ki of U50488 of 11 nM; PDSP Ki Database; http://pdsp.med.unc.edu/pdsp.php) would require a concentration of U50488 at least 10,000 × Ki (110 μM). Consequently, for this experiment, we used a dose of U50488 of 100 μg (~240 μM). As shown in Fig. 3 (and Supplemental Fig. 4), injection of U50488 (100 μg, i.pl.) completely abolished the long-term inhibitory effect of norBNI (3 ng, i.pl.) on U50488-mediated inhibition of PGE2-stimulated thermal alldynia measured 2 and 7 days after norBNI administration. Treatment with this high dose of U50488 alone did not produce a long-term effect on either basal or PGE2-mediated thermal alldynia, nor did U50488 alter the subsequent
U50488-mediated antinociceptive response measured 2 and 7 days later.

**Long-Term Effects of norBNI Are Peripherally Restricted.** To verify the peripheral selectivity of the action of drugs injected into the hind paw, we routinely test for effects using the contralateral paw (e.g., Berg et al., 2011; Jamshidi et al., 2015). As shown in Fig. 4 and Supplemental Fig. 5, injection of norBNI to the paw contralateral to the injection of PGE2/U50488 did not alter U50488-mediated antinociception. Thus, the dose of norBNI administered to the hind paw was not sufficient to reach systemic concentrations that activate receptors in the CNS.

**Long-Term Reduction in KOR Function by norBNI Ex Vivo Is Mediated by JNK.** In cultures of adult rat peripheral sensory neurons, U50488 inhibited PGE2-stimulated cAMP accumulation by 49 ± 6% (Fig. 5A), as we have reported before (Berg et al., 2011; Jamshidi et al., 2015). Similarly, the DOR agonist, DPDPE, and the MOR agonist, DAMGO, inhibited PGE2-stimulated cAMP accumulation and that norBNI can be washed away such that the U50488 response is restored.

**Treatment with norBNI Does Not Produce Long-Term Inhibition of KOR-Mediated Activation of ERK.** We have shown before that activation of KOR with U50488 increases ERK activity in peripheral sensory neurons (Berg et al., 2011; Jamshidi et al., 2015). To determine whether long-term effects of norBNI extend to pathways other than cAMP signaling, we measured U50488-mediated activation of ERK after treatment with norBNI (3 nM) 24 hours earlier. As shown in Fig. 5C, treatment of peripheral sensory neurons with U50488 increased ERK phosphorylation (pERK). Interestingly and
in contrast to the long-term inhibition of U50488-mediated inhibition of cAMP accumulation, norBNI treatment did not alter the U50488-mediated increases in ERK activity when tested 24 hours later.

**Fig. 5.** norBNI treatment produces long-term inhibition of U50488-mediated inhibition of PGE2-stimulated cAMP accumulation, but not U50488 stimulation of ERK. (A) Peripheral sensory neuron cultures were pretreated with norBNI (3 nM) or vehicle. After a 1-hour incubation, cells were washed thoroughly. Twenty-four hours later, cells were treated with PGE2 (1 μM) with U50488 (100 nM), DPDPE (100 nM), DAMGO (1 μM), or vehicle, and cellular cAMP levels were measured after 15 minutes. Data represent the mean ± S.E.M. of cAMP levels expressed as the percentage of PGE2-stimulated cAMP levels of three or four independent experiments. *P < 0.05 compared with vehicle-treated cells. (B) Cells were pretreated with SP600125 (1 μM) or vehicle (Veh) 30 minutes before addition of norBNI (3 nM) or vehicle. After a 1-hour incubation, cells were washed thoroughly and cellular cAMP was determined as in (A). Data were analyzed with one-way ANOVA, followed by Dunnett’s post hoc test. **P < 0.001, ***P < 0.001 compared with vehicle-treated cells. (C) Cells were pretreated with norBNI (3 nM) or vehicle for 1 hour, and washed thoroughly as in (A). Twenty-four hours later, levels of pERK were measured at the indicated time points following stimulation with U50488 (100 nM) in the absence or presence of norBNI (3 nM). pERK levels were measured using the pERK Surefire assay kit from PerkinElmer Life and Analytical Sciences, according to the manufacturer’s protocol. Data are expressed as the percentage increase in pERK over basal (no ligand) activity and represent the mean ± S.E.M. of four to six independent experiments. Data were analyzed with two-way ANOVA, followed by Bonferroni’s post hoc test. **P < 0.001, ***P < 0.001 compared with Veh-pretreated cells.

**Discussion**

Kappa opioid receptors expressed by peripheral pain-sensing neurons can produce robust antinociception; however, several cellular regulatory mechanisms, which may be unique to nociceptors, limit antinociceptive effectiveness of peripherally-restricted KOR agonists (Patwardhan et al., 2005; Berg et al., 2007, 2011; Rowan et al., 2009; Jamshidi et al., 2015; Sullivan et al., 2015). If peripheral KOR is to be a viable therapeutic target for peripherally-restricted analgesics, it is important to understand these regulatory mechanisms.

The prototypical KOR antagonist, norBNI, along with some other, but not all, KOR antagonists, can produce long-lasting inhibition of KOR function in the CNS and in heterologous expression systems (Endoh et al., 1992; Horan et al., 1992; Jones and Holtzman, 1992; Butelman et al., 1993; Broadbear et al., 1994; Bruchas et al., 2007b; Melief et al., 2010, 2011). In this study, a single injection of norBNI, injected locally into the plantar surface of the rat hind paw at peripherally-restricted doses, inhibited KOR agonist-mediated antinociception for up to 9 days. In cultures of adult rat peripheral sensory neurons, norBNI also produced long-lasting inhibition of KOR agonist-mediated inhibition of PGE2-stimulated cAMP accumulation, but did not inhibit U50488-stimulated ERK activation. The effect of norBNI was peripherally mediated, as U50488-mediated antinociception measured in the paw contralateral to norBNI injection was unaltered. Moreover, norBNI did not alter the antinociceptive effect of the DOR agonist, DPDPE, or the MOR agonist, DAMGO, suggesting that the long-lasting inhibitory effect of norBNI in the hind paw may be selective for KOR. The long-term effect of norBNI was mediated through...
interaction with KOR because occupancy of KOR with a relatively higher dose of U50488 blocked the long-term effect of norBNI in the hind paw. Chavkin’s group also found that protection of KOR by occupancy with naloxone or buprenorphine (in MOR-knockout mice) blocked the long-term inhibitory effect of systemic norBNI on KOR-mediated antinociception in the tail-flick assay (Bruchas et al., 2007b).

Long-lasting inhibitory effects of norBNI on central KOR function were found to be JNK dependent (Bruchas et al., 2007b; Melief et al., 2010, 2011). The long-term inhibitory effect of norBNI on peripheral KOR function was also dependent upon activation of JNK. norBNI also increased pJNK levels in cultured sensory neurons, as has been reported in mouse brain and HEK cells (Bruchas et al., 2007b; Melief et al., 2010, 2011). Although norBNI is generally considered to be a prototypical KOR antagonist (Portoghese et al., 1987a,b), these results indicate that norBNI is a biased KOR agonist, acting acutely as an antagonist for Ga<sub>i</sub>-mediated effects (antinociception and inhibition of adenylyl cyclase activity), but an agonist for the JNK signaling pathway.

It has been suggested that prolonged KOR antagonism may be due to pharmacokinetic and/or physiochemical properties of norBNI (Patkar et al., 2013). Decreases in maximal [3H]U69593 binding, with no change in KD, were found in mouse brain membranes up to 7 days following systemic injection of norBNI (10 mg/kg, i.p.) (Patkar et al., 2013). Although these data are consistent with prolonged occupancy of KOR, others have not observed changes in KOR agonist binding (Bruchas et al., 2007b). We found that although norBNI treatment blocked U50488-mediated inhibition of adenylyl cyclase activity measured 24 hours after administration in cultured sensory neurons, it did not block U50488-mediated increases in ERK activity, a response that is sensitive to acute norBNI antagonism. Together with the requirement for JNK activation, the results suggest that the long-lasting inhibitory effects of norBNI in peripheral sensory neurons are not due to persistent antagonism by occupancy of KOR, but via a cellular signaling mechanism.

![Fig. 6.](#) The long-term inhibitory effect of norBNI in vivo (A–D) and in peripheral sensory neuron cultures (E and F) is blocked by inhibitors of protein translation. (A–D) Rats received injections (i.pl.) of CHX (25 µg; A and B), RAPA (12 µg; C and D), or vehicle (Veh) 30 minutes prior to and 24 hours following injection (i.pl.) of norBNI (30 ng) or vehicle. Two (A and C) and 7 days (B and D) following norBNI injection, rats received coinjections (i.pl.) of PGE<sub>2</sub> (0.3 µg) with U50488 (0.1 µg) or vehicle. PWL in response to application of a radiant heat stimulus to the ventral surface of the hind paw was measured in duplicate before and at 5-minute intervals following the PGE<sub>2</sub>/U50488 coinjection. Data are expressed as the mean ± S.E.M. of the AUC for each group of six animals. Data were analyzed with one-way ANOVA and Dunnett’s post hoc test. **P < 0.01, ***P < 0.001 compared with vehicle-treated rats. Time course data are provided in Supplemental Fig. 6. (E and F) Peripheral sensory neurons in culture were treated with CHX (1 µM), RAPA (1 µM), or vehicle 30 minutes before norBNI (3 nM) or vehicle treatment of 1 hour, followed by washing. Twenty-four hours later, cells treated with PGE<sub>2</sub> (1 µM) with or without U50488 (100 nM) and cellular levels of cAMP were measured. Data are expressed as percentage of PGE<sub>2</sub>-stimulated cAMP levels and represent the mean ± S.E.M. of four experiments. Data were analyzed with a one-way ANOVA with Dunnett’s post hoc test; ***P < 0.001, **P < 0.01 in comparison with vehicle-pretreated conditions, ##P < 0.01, ###P < 0.001 compared to norBNI treated rats.
that interferes with some (inhibition of adenylyl cyclase, antinociception), but not all (activation of ERK), KOR responses.

In addition to norBNI and some other antagonists (Bruchas et al., 2007b; Melief et al., 2011), activation of KOR with some prototypical agonist ligands (e.g., U50488, U69598) can also stimulate JNK activation (Kam et al., 2004; Bruchas et al., 2007b). However, U50488 does not elicit long-term inhibition of KOR function in rat peripheral sensory neurons or in mice (Bruchas et al., 2007b). It is notable that U50488-mediated JNK activation, but not that of norBNI, is sensitive to pertussis toxin (Bruchas et al., 2007b), suggesting that whereas U50488 activates JNK via KOR coupling to Gi proteins, norBNI-mediated JNK activation is Gi independent. It has been shown that the functional consequences of activation of the mitogen-activated protein kinase, ERK, can differ markedly depending upon the mechanism (Go protein versus non-Go protein mediation) by which ERK is activated (Azzi et al., 2003; Tohgo et al., 2003; Ahn et al., 2004; Kohout et al., 2004; Shenoy et al., 2006; Zheng et al., 2008), although, to our knowledge, similar studies have not been conducted for JNK.

The long-term inhibitory effect of norBNI on peripheral KOR function in vivo and ex vivo was blocked by two protein translation inhibitors with different mechanisms of action, CHX and RAPA. These results also suggest that the long-lasting effect of norBNI was not due to continued receptor occupancy by norBNI or a metabolite. Instead, a newly synthesized protein appears to mediate the long-term action of norBNI. Although effective when injected into the hind paw before norBNI, when protein translation inhibitors were administered 5–6 days after norBNI, they were ineffective. This suggests that a protein involved in norBNI-mediated long-term inhibition of KOR antinociceptive signaling is synthesized relatively early in response to activation of JNK, and it, or its effect, remains to inhibit KOR responsiveness for several days. Although norBNI produces long-term inhibitory effects in the CNS that are mediated by JNK activation, it is not known whether de novo protein synthesis is involved. Given that opioid receptor regulation in peripheral sensory neurons differs from that for receptors expressed on CNS neurons (e.g., see Sullivan et al., 2015), it is possible that mechanisms underlying long-term effects of norBNI may also differ.

In addition to its well-known role as a regulator of transcription, JNK also regulates protein translation (Swantek et al., 1997; Patel et al., 2012; Li et al., 2015). This suggests that norBNI activation of KOR increases JNK activity that in turn increased translation of mRNA in the nerve terminals of the hind paw to produce a protein that caused long-lasting inhibition of KOR agonist-mediated antinociception. Although once controversial, there is now substantial evidence that mRNA, ribosomes, and other elements required for protein translation are present and active in mammalian axons and nerve terminals (Bramham and Wells, 2007; Jimenez-Diaz et al., 2008; Mlemedjian et al., 2010; Willis and Twiss, 2010; Obara et al., 2012; Ferrari et al., 2013). Considering the long distance between the nucleus and the nerve terminals in sensory neurons, it seems likely that the mRNA translated by KOR activation is resident in the nerve terminals awaiting a signal to initiate translation.

The presence of mRNA and local protein translation machinery is energetically favorable and facilitates dynamic regulation of signaling in nerve terminals. Although regulation of protein synthesis in dendrites or nerve terminals is influenced by neuronal activity (Bramham and Wells, 2007; Willis and Twiss, 2010), there are very few reports that have demonstrated regulation of local protein synthesis in synaptic regions by G protein–coupled receptors (GPCRs). Increased local protein synthesis in synaptic regions of hippocampal neurons has been attributed to activation of metabotropic glutamate receptors in cultured neurons, hippocampal slices, and synaptoneurosomes (Shin et al., 2004; Mockett et al., 2011). Activation of dopamine D1/D5 receptors stimulates local synthesis of the GluR1 subunit of the AMPA receptor in dendrites of cultured hippocampal neurons (Smith et al., 2005) and increases the synthesis of synapse-associated protein 90/postsynaptic density protein 95-associated protein 3 in cultured prefrontal cortical neurons and slices (Wang et al., 2010). In this work, we provide evidence for local protein synthesis regulated by KOR activation with norBNI in sensory nerve terminals in vivo. Although evidence supporting regulation of local protein synthesis by GPCRs is scarce, it is well known that key mRNA translational control proteins, such as certain cytoplasmic polyadenylation element-binding proteins, eukaryotic translation initiation factors, and eukaryotic elongation factors, are regulated by cellular kinases that are known effectors of GPCRs, such as ERK, calcium-calmodulin–dependent protein kinase II, and mammalian target of rapamycin (Bramham and Wells, 2007). Thus, GPCR-mediated regulation of local protein synthesis in dendrites and nerve terminals may be more common than previously thought.

In summary, in peripheral sensory neurons, norBNI interaction with KOR activates JNK, resulting in long-term inhibition of KOR-mediated antinociception in vivo and inhibition of adenylyl cyclase activity in cultured neurons. These findings support and extend the work of the Chavkin group, who originally identified the role of JNK in the long-term regulation of KOR by norBNI and other antagonists in the CNS and in HEK cells (Bruchas et al., 2007b; Melief et al., 2010, 2011). KOR-dependent activation of JNK indicates that norBNI, and perhaps other long-acting KOR ligands, are not pure antagonists, but instead function as biased ligands. Importantly, the long-term effect of norBNI to selectively regulate KOR function required new protein synthesis in sensory nerve terminals. This new protein(s) functions to inhibit KOR-mediated antinociception and inhibition of adenylyl cyclase activity, but not activation of ERK. Currently, the identification of the protein(s) that regulates KOR function, and its mechanism of action, awaits further investigation. It is intriguing to speculate about the nature of the physiologic conditions that might lead to activation of this long-term inhibitory pathway.

Acknowledgments

We thank Dr. Tom Prisinzano for the generous gift of Salvinorin A, Dr. Elaine Jennings for help with experiments and for constructive criticisms, and Peter LoCoco for helpful comments.
Authorship Contributions
Participated in research design: Berg, Clarke, Jamshidi.
Conducted experiments: Chavera, Jamshidi, Jacobs, Sullivan.
Performed data analysis: Berg, Clarke, Jamshidi.
Wrote or contributed to the writing of the manuscript: Berg, Clarke, Jamshidi.

References

Mol Pharmacol 81:564–574.
Molec Pharmacol 8:1292.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.
Handb Exp Pharmacol 119.1–119.2.


Address correspondence to: Dr. Kelly A. Berg, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900. E-mail: berg@uthscsa.edu